Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
20.19
-0.25 (-1.22%)
At close: Oct 21, 2026, 4:00 PM EDT
20.00
-0.19 (-0.94%)
After-hours: Oct 21, 2026, 5:15 PM EDT
Acadia Pharmaceuticals Revenue
Acadia Pharmaceuticals had revenue of $307.96M in the quarter ending June 30, 2026, with 16.40% growth. This brings the company's total for the last twelve months to $1.14B, up 11.75% year-over-year. In the year 2025, Acadia Pharmaceuticals had annual revenue of $1.07B with 11.87% growth. That makes Acadia Pharmaceuticals the 7,042nd largest company in the world by revenue and 1,707th in the United States.
Revenue (ttm)
$1.14B
Revenue Growth
+11.75%
P/S Ratio
3.05
Revenue / Employee
$1,426,872
Employees
798
Market Cap
3.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 113.71M | 11.87% |
| Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
| Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
| Dec 31, 2018 | 223.81M | 98.91M | 79.19% |
| Dec 31, 2017 | 124.90M | 107.57M | 620.68% |
| Dec 31, 2016 | 17.33M | 17.27M | 28,311.48% |
| Dec 31, 2015 | 61.00K | -59.00K | -49.17% |
| Dec 31, 2014 | 120.00K | -1.03M | -89.52% |
| Dec 31, 2013 | 1.15M | -3.76M | -76.67% |
| Dec 31, 2012 | 4.91M | 2.84M | 137.40% |
| Dec 31, 2011 | 2.07M | -40.07M | -95.09% |
| Dec 31, 2010 | 42.14M | 35.74M | 558.46% |
| Dec 31, 2009 | 6.40M | 4.81M | 302.45% |
| Dec 31, 2008 | 1.59M | -5.97M | -78.95% |
| Dec 31, 2007 | 7.56M | -578.00K | -7.11% |
| Dec 31, 2006 | 8.13M | -2.82M | -25.77% |
| Dec 31, 2005 | 10.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
ACAD News
- 8 days ago - Acadia Pharmaceuticals Slides: Corporate presentation - Filings
- 8 days ago - Acadia Pharmaceuticals downgraded to Neutral from Buy at UBS - TheFly
- 13 days ago - Acadia Pharmaceuticals price target lowered to $36 from $37 at RBC Capital - TheFly
- 16 days ago - Acadia looks to have settled case with Zydus, says RBC Capital - TheFly
- 23 days ago - Acadia Pharmaceuticals announces USPTO allowance of patent covering Trofinetide - TheFly
- 23 days ago - Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Business Wire
- 26 days ago - Acadia price target lowered to $33 from $37 at H.C. Wainwright - TheFly
- 26 days ago - Acadia Pharmaceuticals price target lowered to $35 from $41 at Needham - TheFly